{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T02:06:52Z","timestamp":1794622012120,"version":"4.9.1"},"reference-count":244,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Advances in cancer immunotherapy over the last decade have led to the development of several agents that affect immune checkpoints. Inhibitory receptors expressed on T cells that negatively regulate the immune response include cytotoxic T\u2011lymphocyte antigen 4 (CTLA4) and programmed cell death protein 1 (PD1), which have been studied more than similar receptors. Inhibition of these proteins and other immune checkpoints can stimulate the immune system to attack cancer cells, and prevent the tumor from escaping the immune response. However, the administration of anti-PD1 and anti-CTLA4 antibodies has been associated with adverse inflammatory responses similar to autoimmune diseases. The current review discussed the role of the NF-\u03baB pathway as a tumor promoter, and how it can govern inflammatory responses and affect various immune checkpoints. More precise knowledge about the communication between immune checkpoints and NF-\u03baB pathways could increase the effectiveness of immunotherapy and reduce the adverse effects of checkpoint inhibitor therapy.<\/jats:p>\n                <jats:p><jats:bold>Graphical abstract<\/jats:bold><\/jats:p>","DOI":"10.1007\/s00018-023-05098-8","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T04:34:01Z","timestamp":1709181241000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":101,"title":["Targeting the NF-\u03baB pathway as a potential regulator of immune checkpoints in cancer immunotherapy"],"prefix":"10.1007","volume":"81","author":[{"given":"Nasim","family":"Ebrahimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al-Hasnawi Rasool Riyadh","family":"Abdulwahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atena","family":"Mansouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasrin","family":"Karimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashid Jafardoust","family":"Bostani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheida","family":"Beiranvand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samaneh","family":"Adelian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roya","family":"Khorram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Vafadar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Hamblin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Reza","family":"Aref","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,29]]},"reference":[{"issue":"s2","key":"5098_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3747\/co.27.5223","volume":"27","author":"K Esfahani","year":"2020","unstructured":"Esfahani K et al (2020) A review of cancer immunotherapy: from the past, to the present, to the future. Curr Oncol 27(s2):87\u201397","journal-title":"Curr Oncol"},{"key":"5098_CR2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3389\/fimmu.2014.00197","volume":"5","author":"A Corthay","year":"2014","unstructured":"Corthay A (2014) Does the immune system naturally protect against cancer? Front Immunol 5:197","journal-title":"Front Immunol"},{"issue":"3","key":"5098_CR3","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nri2506","volume":"9","author":"DI Gabrilovich","year":"2009","unstructured":"Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9(3):162\u2013174","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"5098_CR4","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ (2020) A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol 20(11):651\u2013668","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"5098_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-019-1266-0","volume":"38","author":"S Kruger","year":"2019","unstructured":"Kruger S et al (2019) Advances in cancer immunotherapy 2019\u2013latest trends. J Exp Clin Cancer Res 38(1):1\u201311","journal-title":"J Exp Clin Cancer Res"},{"key":"5098_CR6","first-page":"1","volume":"21","author":"N Ebrahimi","year":"2021","unstructured":"Ebrahimi N et al (2021) Development of neoantigens: from identification in cancer cells to application in cancer vaccines. Expert Rev Vaccines 21:1\u201315","journal-title":"Expert Rev Vaccines"},{"issue":"8","key":"5098_CR7","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711\u2013723","journal-title":"N Engl J Med"},{"issue":"26","key":"5098_CR8","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert C et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26):2517\u20132526","journal-title":"N Engl J Med"},{"issue":"2","key":"5098_CR9","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.coi.2011.12.009","volume":"24","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Drake CG, Pardoll DM (2012) Targeting the PD-1\/B7-H1 (PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 24(2):207\u2013212","journal-title":"Curr Opin Immunol"},{"issue":"10027","key":"5098_CR10","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387(10027):1540\u20131550","journal-title":"Lancet"},{"issue":"1","key":"5098_CR11","doi-asserted-by":"publisher","first-page":"76","DOI":"10.14694\/EdBook_AM.2015.35.76","volume":"35","author":"MA Postow","year":"2015","unstructured":"Postow MA (2015) Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book 35(1):76\u201383","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"32","key":"5098_CR12","doi-asserted-by":"publisher","first-page":"5275","DOI":"10.1200\/JCO.2008.17.8954","volume":"26","author":"L Fong","year":"2008","unstructured":"Fong L, Small EJ (2008) Anti\u2013cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol 26(32):5275\u20135283","journal-title":"J Clin Oncol"},{"key":"5098_CR13","doi-asserted-by":"crossref","unstructured":"Kobayashi Y, Lim S-O, Yamaguchi H (2020) Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer. In: Seminars in cancer biology. Elsevier","DOI":"10.1016\/j.semcancer.2019.11.011"},{"issue":"1\u20132","key":"5098_CR14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2016.12.012","volume":"168","author":"Q Zhang","year":"2017","unstructured":"Zhang Q, Lenardo MJ, Baltimore D (2017) 30 years of NF-\u03baB: a blossoming of relevance to human pathobiology. Cell 168(1\u20132):37\u201357","journal-title":"Cell"},{"key":"5098_CR15","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.neulet.2016.05.066","volume":"627","author":"L Zuo","year":"2016","unstructured":"Zuo L, Shi L, Yan F (2016) The reciprocal interaction of sympathetic nervous system and cAMP-PKA-NF-kB pathway in immune suppression after experimental stroke. Neurosci Lett 627:205\u2013210","journal-title":"Neurosci Lett"},{"issue":"5","key":"5098_CR16","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/0092-8674(86)90346-6","volume":"46","author":"R Sen","year":"1986","unstructured":"Sen R, Baltimore D (1986) Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 46(5):705\u2013716","journal-title":"Cell"},{"issue":"8","key":"5098_CR17","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/ni.2072","volume":"12","author":"D Baltimore","year":"2011","unstructured":"Baltimore D (2011) NF-\u03baB is 25. Nat Immunol 12(8):683\u2013685","journal-title":"Nat Immunol"},{"issue":"1","key":"5098_CR18","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/j.1600-065X.2011.01091.x","volume":"246","author":"ST Smale","year":"2012","unstructured":"Smale ST (2012) Dimer-specific regulatory mechanisms within the NF-\u03baB family of transcription factors. Immunol Rev 246(1):193\u2013204","journal-title":"Immunol Rev"},{"issue":"3","key":"5098_CR19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1101\/gad.183434.111","volume":"26","author":"MS Hayden","year":"2012","unstructured":"Hayden MS, Ghosh S (2012) NF-\u03baB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev 26(3):203\u2013234","journal-title":"Genes Dev"},{"issue":"3","key":"5098_CR20","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.cell.2008.01.020","volume":"132","author":"MS Hayden","year":"2008","unstructured":"Hayden MS, Ghosh S (2008) Shared principles in NF-\u03baB signaling. Cell 132(3):344\u2013362","journal-title":"Cell"},{"issue":"8","key":"5098_CR21","doi-asserted-by":"publisher","first-page":"5018","DOI":"10.1128\/jvi.66.8.5018-5029.1992","volume":"66","author":"W Walker","year":"1992","unstructured":"Walker W et al (1992) The v-rel oncogene: insights into the mechanism of transcriptional activation, repression, and transformation. J Virol 66(8):5018\u20135029","journal-title":"J Virol"},{"issue":"1","key":"5098_CR22","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/jbmr.2590","volume":"31","author":"AL Frederiksen","year":"2016","unstructured":"Frederiksen AL et al (2016) Neonatal high bone mass with first mutation of the NF-\u03baB complex: heterozygous de novo missense (p. Asp512Ser) RELA (Rela\/p65). J Bone Miner Res 31(1):163\u2013172","journal-title":"J Bone Miner Res"},{"issue":"20","key":"5098_CR23","doi-asserted-by":"publisher","first-page":"5530","DOI":"10.1093\/emboj\/cdg534","volume":"22","author":"A Hoffmann","year":"2003","unstructured":"Hoffmann A, Leung TH, Baltimore D (2003) Genetic analysis of NF-\u03baB\/Rel transcription factors defines functional specificities. EMBO J 22(20):5530\u20135539","journal-title":"EMBO J"},{"issue":"1","key":"5098_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms8068","volume":"6","author":"R Tsui","year":"2015","unstructured":"Tsui R et al (2015) I\u03baB\u03b2 enhances the generation of the low-affinity NF\u03baB\/RelA homodimer. Nat Commun 6(1):1\u201310","journal-title":"Nat Commun"},{"key":"5098_CR25","volume-title":"NF-\u03baB-related genetic diseases","author":"G Courtois","year":"2015","unstructured":"Courtois G et al (2015) NF-\u03baB-related genetic diseases. Springer"},{"issue":"9","key":"5098_CR26","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.1073\/pnas.1222878110","volume":"110","author":"J Seok","year":"2013","unstructured":"Seok J et al (2013) Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci 110(9):3507\u20133512","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"5098_CR27","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1073\/pnas.1401965111","volume":"112","author":"K Takao","year":"2015","unstructured":"Takao K, Miyakawa T (2015) Genomic responses in mouse models greatly mimic human inflammatory diseases. Proc Natl Acad Sci 112(4):1167\u20131172","journal-title":"Proc Natl Acad Sci"},{"key":"5098_CR28","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3389\/fendo.2018.00471","volume":"9","author":"C Giuliani","year":"2018","unstructured":"Giuliani C, Bucci I, Napolitano G (2018) The role of the transcription factor nuclear factor-kappa B in thyroid autoimmunity and cancer. Front Endocrinol 9:471","journal-title":"Front Endocrinol"},{"issue":"3","key":"5098_CR29","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.gendis.2020.06.005","volume":"8","author":"MR Zinatizadeh","year":"2021","unstructured":"Zinatizadeh MR et al (2021) The Nuclear Factor Kappa B (NF-kB) signaling in cancer development and immune diseases. Genes Dis 8(3):287\u2013297","journal-title":"Genes Dis"},{"issue":"9","key":"5098_CR30","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/nri.2017.52","volume":"17","author":"S-C Sun","year":"2017","unstructured":"Sun S-C (2017) The non-canonical NF-\u03baB pathway in immunity and inflammation. Nat Rev Immunol 17(9):545\u2013558","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"5098_CR31","first-page":"1","volume":"2","author":"T Liu","year":"2017","unstructured":"Liu T et al (2017) NF-\u03baB signaling in inflammation. Signal Transduct Target Ther 2(1):1\u20139","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"5098_CR32","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.it.2004.03.008","volume":"25","author":"G Bonizzi","year":"2004","unstructured":"Bonizzi G, Karin M (2004) The two NF-\u03baB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25(6):280\u2013288","journal-title":"Trends Immunol"},{"issue":"1","key":"5098_CR33","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1146\/annurev.immunol.20.083001.084359","volume":"20","author":"CA Janeway Jr","year":"2002","unstructured":"Janeway CA Jr, Medzhitov R (2002) Innate immune recognition. Annu Rev Immunol 20(1):197\u2013216","journal-title":"Annu Rev Immunol"},{"key":"5098_CR34","doi-asserted-by":"crossref","unstructured":"Mak TW, Saunders ME (2006) The immune response. Part I: basic immunology, pp 373\u2013401","DOI":"10.1016\/B978-012088451-3\/50016-8"},{"issue":"1","key":"5098_CR35","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1146\/annurev.immunol.16.1.225","volume":"16","author":"S Ghosh","year":"1998","unstructured":"Ghosh S, May MJ, Kopp EB (1998) NF-\u03baB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16(1):225\u2013260","journal-title":"Annu Rev Immunol"},{"issue":"8","key":"5098_CR36","doi-asserted-by":"publisher","first-page":"4453","DOI":"10.4049\/jimmunol.163.8.4453","volume":"163","author":"J Caama\u00f1o","year":"1999","unstructured":"Caama\u00f1o J et al (1999) The NF-\u03baB family member RelB is required for innate and adaptive immunity to Toxoplasma gondii. J Immunol 163(8):4453\u20134461","journal-title":"J Immunol"},{"issue":"24","key":"5098_CR37","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1002\/j.1460-2075.1996.tb01101.x","volume":"15","author":"G Grigoriadis","year":"1996","unstructured":"Grigoriadis G et al (1996) The Rel subunit of NF-kappaB-like transcription factors is a positive and negative regulator of macrophage gene expression: distinct roles for Rel in different macrophage populations. EMBO J 15(24):7099\u20137107","journal-title":"EMBO J"},{"issue":"6","key":"5098_CR38","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.4049\/jimmunol.168.6.2590","volume":"168","author":"N Mason","year":"2002","unstructured":"Mason N et al (2002) Cutting edge: identification of c-Rel-dependent and-independent pathways of IL-12 production during infectious and inflammatory stimuli. J Immunol 168(6):2590\u20132594","journal-title":"J Immunol"},{"issue":"1","key":"5098_CR39","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/0952-7915(95)80026-3","volume":"7","author":"P Scott","year":"1995","unstructured":"Scott P, Trinchieri G (1995) The role of natural killer cells in host\u2014parasite interactions. Curr Opin Immunol 7(1):34\u201340","journal-title":"Curr Opin Immunol"},{"issue":"6980","key":"5098_CR40","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nature02405","volume":"428","author":"L-C Hsu","year":"2004","unstructured":"Hsu L-C et al (2004) The protein kinase PKR is required for macrophage apoptosis after activation of Toll-like receptor 4. Nature 428(6980):341\u2013345","journal-title":"Nature"},{"issue":"4","key":"5098_CR41","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/0092-8674(90)90146-6","volume":"63","author":"DW Ballard","year":"1990","unstructured":"Ballard DW et al (1990) The v-rel oncogene encodes a \u03baB enhancer binding protein that inhibits NF-\u03baB function. Cell 63(4):803\u2013814","journal-title":"Cell"},{"issue":"1","key":"5098_CR42","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","volume":"100","author":"D Hanahan","year":"2000","unstructured":"Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57\u201370","journal-title":"Cell"},{"issue":"3","key":"5098_CR43","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.cell.2004.07.013","volume":"118","author":"FR Greten","year":"2004","unstructured":"Greten FR et al (2004) IKK\u03b2 links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118(3):285\u2013296","journal-title":"Cell"},{"issue":"15","key":"5098_CR44","doi-asserted-by":"publisher","first-page":"5202","DOI":"10.1158\/1078-0432.CCR-03-0537","volume":"10","author":"D Mezzanzanica","year":"2004","unstructured":"Mezzanzanica D et al (2004) CD95-mediated apoptosis is impaired at receptor level by cellular FLICE-inhibitory protein (long form) in wild-type p53 human ovarian carcinoma. Clin Cancer Res 10(15):5202\u20135214","journal-title":"Clin Cancer Res"},{"issue":"5","key":"5098_CR45","first-page":"1059","volume":"63","author":"X Chen","year":"2003","unstructured":"Chen X, Kandasamy K, Srivastava RK (2003) Differential roles of RelA (p65) and c-Rel subunits of nuclear factor \u03baB in tumor necrosis factor-related apoptosis-inducing ligand signaling. Can Res 63(5):1059\u20131066","journal-title":"Can Res"},{"key":"5098_CR46","first-page":"262","volume":"88","author":"RT Lee","year":"2001","unstructured":"Lee RT, Collins T (2001) Nuclear factor-\u03baB and cell survival: IAPs call for support. Am Heart Assoc 88:262\u2013264","journal-title":"Am Heart Assoc"},{"issue":"10","key":"5098_CR47","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1172\/JCI26251","volume":"115","author":"CW Wright","year":"2005","unstructured":"Wright CW, Duckett CS (2005) Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function. J Clin Investig 115(10):2673\u20132678","journal-title":"J Clin Investig"},{"issue":"13","key":"5098_CR48","doi-asserted-by":"publisher","first-page":"11345","DOI":"10.1074\/jbc.M109893200","volume":"277","author":"X-M Sun","year":"2002","unstructured":"Sun X-M et al (2002) Bcl-2 and Bcl-xL inhibit CD95-mediated apoptosis by preventing mitochondrial release of Smac\/DIABLO and subsequent inactivation of X-linked inhibitor-of-apoptosis protein. J Biol Chem 277(13):11345\u201311351","journal-title":"J Biol Chem"},{"issue":"24","key":"5098_CR49","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.1038\/sj.onc.1205489","volume":"21","author":"S Delhalle","year":"2002","unstructured":"Delhalle S et al (2002) NF-\u03baB-dependent MnSOD expression protects adenocarcinoma cells from TNF-\u03b1-induced apoptosis. Oncogene 21(24):3917\u20133924","journal-title":"Oncogene"},{"issue":"1","key":"5098_CR50","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nrc1256","volume":"4","author":"JW Pollard","year":"2004","unstructured":"Pollard JW (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4(1):71\u201378","journal-title":"Nat Rev Cancer"},{"issue":"14","key":"5098_CR51","doi-asserted-by":"publisher","first-page":"4858","DOI":"10.1158\/0008-5472.CAN-04-0682","volume":"64","author":"EV Bobrovnikova-Marjon","year":"2004","unstructured":"Bobrovnikova-Marjon EV et al (2004) Expression of angiogenic factors vascular endothelial growth factor and interleukin-8\/CXCL8 is highly responsive to ambient glutamine availability: role of nuclear factor-\u03baB and activating protein-1. Can Res 64(14):4858\u20134869","journal-title":"Can Res"},{"issue":"10","key":"5098_CR52","doi-asserted-by":"publisher","first-page":"6038","DOI":"10.1074\/jbc.C800207200","volume":"284","author":"D Martin","year":"2009","unstructured":"Martin D, Galisteo R, Gutkind JS (2009) CXCL8\/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NF\u03baB through the CBM (Carma3\/Bcl10\/Malt1) complex. J Biol Chem 284(10):6038\u20136042","journal-title":"J Biol Chem"},{"issue":"1","key":"5098_CR53","first-page":"255","volume":"23","author":"W Wu","year":"2010","unstructured":"Wu W et al (2010) Hypoxia activates heparanase expression in an NF-\u03baB dependent manner. Oncol Rep 23(1):255\u2013261","journal-title":"Oncol Rep"},{"issue":"2","key":"5098_CR54","first-page":"409","volume":"40","author":"M Tomonaga","year":"2012","unstructured":"Tomonaga M et al (2012) Activation of nuclear factor-kappa B by linear ubiquitin chain assembly complex contributes to lung metastasis of osteosarcoma cells. Int J Oncol 40(2):409\u2013417","journal-title":"Int J Oncol"},{"issue":"22","key":"5098_CR55","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.3748\/wjg.v10.i22.3255","volume":"10","author":"L-L Yu","year":"2004","unstructured":"Yu L-L et al (2004) Nuclear factor-kB p65 (RelA) transcription factor is constitutively activated in human colorectal carcinoma tissue. World J Gastroenterol: WJG 10(22):3255","journal-title":"World J Gastroenterol: WJG"},{"issue":"23","key":"5098_CR56","doi-asserted-by":"publisher","first-page":"10391","DOI":"10.1128\/MCB.25.23.10391-10406.2005","volume":"25","author":"I Lamsoul","year":"2005","unstructured":"Lamsoul I et al (2005) Exclusive ubiquitination and sumoylation on overlapping lysine residues mediate NF-\u03baB activation by the human T-cell leukemia VirusTax oncoprotein. Mol Cell Biol 25(23):10391\u201310406","journal-title":"Mol Cell Biol"},{"issue":"1","key":"5098_CR57","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/genes9010024","volume":"9","author":"BR Pires","year":"2018","unstructured":"Pires BR et al (2018) NF-kappaB: two sides of the same coin. Genes 9(1):24","journal-title":"Genes"},{"issue":"9","key":"5098_CR58","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1158\/2326-6066.CIR-14-0112","volume":"2","author":"Y Xia","year":"2014","unstructured":"Xia Y, Shen S, Verma IM (2014) NF-\u03baB, an active player in human cancers. Cancer Immunol Res 2(9):823\u2013830","journal-title":"Cancer Immunol Res"},{"issue":"7092","key":"5098_CR59","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nature04870","volume":"441","author":"M Karin","year":"2006","unstructured":"Karin M (2006) Nuclear factor-\u03baB in cancer development and progression. Nature 441(7092):431\u2013436","journal-title":"Nature"},{"issue":"6","key":"5098_CR60","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","volume":"140","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140(6):883\u2013899","journal-title":"Cell"},{"issue":"2","key":"5098_CR61","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/cells5020015","volume":"5","author":"MH Park","year":"2016","unstructured":"Park MH, Hong JT (2016) Roles of NF-\u03baB in cancer and inflammatory diseases and their therapeutic approaches. Cells 5(2):15","journal-title":"Cells"},{"issue":"1","key":"5098_CR62","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrd2781","volume":"8","author":"V Baud","year":"2009","unstructured":"Baud V, Karin M (2009) Is NF-\u03baB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8(1):33\u201340","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"5098_CR63","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nrc2734","volume":"9","author":"H Yu","year":"2009","unstructured":"Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9(11):798\u2013809","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"5098_CR64","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cytogfr.2009.11.005","volume":"21","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov SI, Karin M (2010) Dangerous liaisons: STAT3 and NF-\u03baB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 21(1):11\u201319","journal-title":"Cytokine Growth Factor Rev"},{"issue":"5","key":"5098_CR65","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a000182","volume":"2","author":"S Gerondakis","year":"2010","unstructured":"Gerondakis S, Siebenlist U (2010) Roles of the NF-\u03baB pathway in lymphocyte development and function. Cold Spring Harb Perspect Biol 2(5):a000182","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"1","key":"5098_CR66","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/imr.12033","volume":"252","author":"H Oh","year":"2013","unstructured":"Oh H, Ghosh S (2013) NF-\u03baB: roles and regulation in different CD 4+ T-cell subsets. Immunol Rev 252(1):41\u201351","journal-title":"Immunol Rev"},{"issue":"4","key":"5098_CR67","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/ijc.25429","volume":"127","author":"H Nishikawa","year":"2010","unstructured":"Nishikawa H, Sakaguchi S (2010) Regulatory T cells in tumor immunity. Int J Cancer 127(4):759\u2013767","journal-title":"Int J Cancer"},{"issue":"6","key":"5098_CR68","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.cell.2017.08.004","volume":"170","author":"Y Grinberg-Bleyer","year":"2017","unstructured":"Grinberg-Bleyer Y et al (2017) NF-\u03baB c-Rel is crucial for the regulatory T cell immune checkpoint in cancer. Cell 170(6):1096\u20131108","journal-title":"Cell"},{"issue":"10","key":"5098_CR69","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.3390\/biomedicines10102498","volume":"10","author":"D Galizia","year":"2022","unstructured":"Galizia D et al (2022) How risk factors affect head and neck squamous cell carcinoma (HNSCC) tumor immune microenvironment (TIME): their influence on immune escape mechanisms and immunotherapy strategy. Biomedicines 10(10):2498","journal-title":"Biomedicines"},{"issue":"36","key":"5098_CR70","doi-asserted-by":"publisher","first-page":"4828","DOI":"10.1200\/JCO.2011.38.0899","volume":"29","author":"SL Topalian","year":"2011","unstructured":"Topalian SL, Weiner GJ, Pardoll DM (2011) Cancer immunotherapy comes of age. J Clin Oncol 29(36):4828","journal-title":"J Clin Oncol"},{"issue":"1","key":"5098_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-019-0770-2","volume":"7","author":"S Chen","year":"2019","unstructured":"Chen S et al (2019) Mechanisms regulating PD-L1 expression on tumor and immune cells. J Immunother Cancer 7(1):1\u201312","journal-title":"J Immunother Cancer"},{"issue":"3","key":"5098_CR72","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1136\/jclinpath-2017-204853","volume":"71","author":"A Kythreotou","year":"2018","unstructured":"Kythreotou A et al (2018) PD-L1. J Clin Pathol 71(3):189\u2013194","journal-title":"J Clin Pathol"},{"issue":"1","key":"5098_CR73","first-page":"58","volume":"131","author":"B Rowshanravan","year":"2018","unstructured":"Rowshanravan B, Halliday N, Sansom DM (2018) CTLA-4: a moving target in immunotherapy. Blood J Am Soc Hematol 131(1):58\u201367","journal-title":"Blood J Am Soc Hematol"},{"issue":"8","key":"5098_CR74","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1002\/1521-4141(200208)32:8<2095::AID-IMMU2095>3.0.CO;2-E","volume":"32","author":"H Harlin","year":"2002","unstructured":"Harlin H et al (2002) CTLA-4 engagement regulates NF-\u03baB activation in vivo. Eur J Immunol 32(8):2095\u20132104","journal-title":"Eur J Immunol"},{"key":"5098_CR75","doi-asserted-by":"publisher","first-page":"1007326","DOI":"10.3389\/fimmu.2022.1007326","volume":"13","author":"J Chen","year":"2022","unstructured":"Chen J et al (2022) Exploration of the underlying biological differences and targets in ovarian cancer patients with diverse immunotherapy response. Front Immunol 13:1007326","journal-title":"Front Immunol"},{"issue":"5","key":"5098_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.bj.2023.100631","volume":"46","author":"G Forlani","year":"2023","unstructured":"Forlani G et al (2023) The NLR member CIITA: Master controller of adaptive and intrinsic immunity and unexpected tool in cancer immunotherapy. Biomed J 46(5):100631","journal-title":"Biomed J"},{"issue":"12","key":"5098_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","volume":"50","author":"P Darvin","year":"2018","unstructured":"Darvin P et al (2018) Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med 50(12):1\u201311","journal-title":"Exp Mol Med"},{"issue":"328","key":"5098_CR78","doi-asserted-by":"publisher","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","volume":"8","author":"W Zou","year":"2016","unstructured":"Zou W, Wolchok JD, Chen L (2016) PD-L1 (B7\u2013H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med 8(328):328rv4","journal-title":"Sci Transl Med"},{"issue":"1","key":"5098_CR79","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","volume":"20","author":"A Kalbasi","year":"2020","unstructured":"Kalbasi A, Ribas A (2020) Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol 20(1):25\u201339","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"5098_CR80","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei SC, Duffy CR, Allison JP (2018) Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 8(9):1069\u20131086","journal-title":"Cancer Discov"},{"issue":"3","key":"5098_CR81","first-page":"727","volume":"10","author":"Y Han","year":"2020","unstructured":"Han Y, Liu D, Li L (2020) PD-1\/PD-L1 pathway: current researches in cancer. Am J Cancer Res 10(3):727\u2013742","journal-title":"Am J Cancer Res"},{"key":"5098_CR82","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00086","author":"JA Seidel","year":"2018","unstructured":"Seidel JA, Otsuka A, Kabashima K (2018) Anti-PD-1 and Anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2018.00086","journal-title":"Front Oncol"},{"issue":"3","key":"5098_CR83","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.oraloncology.2014.11.014","volume":"51","author":"P Ritprajak","year":"2015","unstructured":"Ritprajak P, Azuma M (2015) Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma. Oral Oncol 51(3):221\u2013228","journal-title":"Oral Oncol"},{"issue":"28","key":"5098_CR84","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.1038\/onc.2017.47","volume":"36","author":"A Bouillez","year":"2017","unstructured":"Bouillez A et al (2017) MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer. Oncogene 36(28):4037\u20134046","journal-title":"Oncogene"},{"issue":"4","key":"5098_CR85","first-page":"1469","volume":"53","author":"J Lucas","year":"2018","unstructured":"Lucas J et al (2018) Upregulation of PD-L1 expression by resveratrol and piceatannol in breast and colorectal cancer cells occurs via HDAC3\/p300-mediated NF-\u03baB signaling. Int J Oncol 53(4):1469\u20131480","journal-title":"Int J Oncol"},{"issue":"6377","key":"5098_CR86","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1126\/science.aao1710","volume":"359","author":"D Pan","year":"2018","unstructured":"Pan D et al (2018) A major chromatin regulator determines resistance of tumor cells to T cell\u2013mediated killing. Science 359(6377):770\u2013775","journal-title":"Science"},{"issue":"7664","key":"5098_CR87","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nature23270","volume":"547","author":"RT Manguso","year":"2017","unstructured":"Manguso RT et al (2017) In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature 547(7664):413\u2013418","journal-title":"Nature"},{"issue":"4","key":"5098_CR88","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061602","volume":"8","author":"G Huang","year":"2013","unstructured":"Huang G et al (2013) NF-\u03baB plays a key role in inducing CD274 expression in human monocytes after lipopolysaccharide treatment. PLoS ONE 8(4):e61602","journal-title":"PLoS ONE"},{"issue":"40","key":"5098_CR89","doi-asserted-by":"publisher","first-page":"15483","DOI":"10.1074\/jbc.RA118.004084","volume":"293","author":"Y Zou","year":"2018","unstructured":"Zou Y et al (2018) The proto-oncogene Bcl3 induces immune checkpoint PD-L1 expression, mediating proliferation of ovarian cancer cells. J Biol Chem 293(40):15483\u201315496","journal-title":"J Biol Chem"},{"issue":"1","key":"5098_CR90","first-page":"296","volume":"110","author":"J Liu","year":"2007","unstructured":"Liu J et al (2007) Plasma cells from multiple myeloma patients express B7\u2013H1 (PD-L1) and increase expression after stimulation with IFN-\u03b3 and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood J Am Soc Hematol 110(1):296\u2013304","journal-title":"Blood J Am Soc Hematol"},{"issue":"8","key":"5098_CR91","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1080\/07357900801941852","volume":"26","author":"Y Qian","year":"2008","unstructured":"Qian Y et al (2008) TLR4 signaling induces B7\u2013H1 expression through MAPK pathways in bladder cancer cells. Cancer Invest 26(8):816\u2013821","journal-title":"Cancer Invest"},{"issue":"12","key":"5098_CR92","doi-asserted-by":"publisher","first-page":"9997","DOI":"10.1002\/jcb.27329","volume":"119","author":"H Li","year":"2018","unstructured":"Li H et al (2018) LPS promotes the expression of PD-L1 in gastric cancer cells through NF-\u03baB activation. J Cell Biochem 119(12):9997\u201310004","journal-title":"J Cell Biochem"},{"issue":"4","key":"5098_CR93","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123410","volume":"10","author":"K Gowrishankar","year":"2015","unstructured":"Gowrishankar K et al (2015) Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-\u03baB. PLoS ONE 10(4):e0123410","journal-title":"PLoS ONE"},{"issue":"4","key":"5098_CR94","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.immuni.2022.03.010","volume":"55","author":"MA Patel","year":"2022","unstructured":"Patel MA, Tavazoie SF (2022) RIP(K)ing away immunotherapy resistance. Immunity 55(4):580\u2013582","journal-title":"Immunity"},{"issue":"4","key":"5098_CR95","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.immuni.2022.03.007","volume":"55","author":"L Cucolo","year":"2022","unstructured":"Cucolo L et al (2022) The interferon-stimulated gene RIPK1 regulates cancer cell intrinsic and extrinsic resistance to immune checkpoint blockade. Immunity 55(4):671-685.e10","journal-title":"Immunity"},{"issue":"43","key":"5098_CR96","doi-asserted-by":"publisher","first-page":"E10119","DOI":"10.1073\/pnas.1802166115","volume":"115","author":"M Kowanetz","year":"2018","unstructured":"Kowanetz M et al (2018) Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti\u2013PD-L1). Proc Natl Acad Sci 115(43):E10119\u2013E10126","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"5098_CR97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-019-1403-9","volume":"38","author":"A Thiem","year":"2019","unstructured":"Thiem A et al (2019) IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression. J Exp Clin Cancer Res 38(1):1\u201315","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"5098_CR98","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1186\/s13046-022-02529-5","volume":"41","author":"A Anichini","year":"2022","unstructured":"Anichini A et al (2022) Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy. J Exp Clin Cancer Res 41(1):325","journal-title":"J Exp Clin Cancer Res"},{"issue":"23","key":"5098_CR99","doi-asserted-by":"publisher","first-page":"12189","DOI":"10.18632\/oncotarget.2608","volume":"5","author":"W Fang","year":"2014","unstructured":"Fang W et al (2014) EBV-driven LMP1 and IFN-\u03b3 up-regulate PD-L1 in nasopharyngeal carcinoma: implications for oncotargeted therapy. Oncotarget 5(23):12189","journal-title":"Oncotarget"},{"issue":"21","key":"5098_CR100","doi-asserted-by":"publisher","first-page":"e01718","DOI":"10.1128\/JVI.01718-16","volume":"91","author":"LW Wang","year":"2017","unstructured":"Wang LW, Jiang S, Gewurz BE (2017) Epstein\u2013Barr virus LMP1-mediated oncogenicity. J Virol 91(21):e01718-e1816","journal-title":"J Virol"},{"issue":"2","key":"5098_CR101","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00262-017-2086-8","volume":"67","author":"N Li","year":"2018","unstructured":"Li N et al (2018) Cross-talk between TNF-\u03b1 and IFN-\u03b3 signaling in induction of B7\u2013H1 expression in hepatocellular carcinoma cells. Cancer Immunol Immunother 67(2):271\u2013283","journal-title":"Cancer Immunol Immunother"},{"key":"5098_CR102","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.imlet.2017.02.006","volume":"184","author":"X Wang","year":"2017","unstructured":"Wang X et al (2017) Inflammatory cytokines IL-17 and TNF-\u03b1 up-regulate PD-L1 expression in human prostate and colon cancer cells. Immunol Lett 184:7\u201314","journal-title":"Immunol Lett"},{"issue":"5","key":"5098_CR103","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1423170","volume":"7","author":"A Asgarova","year":"2018","unstructured":"Asgarova A et al (2018) PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma. Oncoimmunology 7(5):e1423170","journal-title":"Oncoimmunology"},{"key":"5098_CR104","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jss.2019.02.038","volume":"240","author":"D Imai","year":"2019","unstructured":"Imai D et al (2019) IFN-\u03b3 promotes epithelial-mesenchymal transition and the expression of PD-L1 in pancreatic cancer. J Surg Res 240:115\u2013123","journal-title":"J Surg Res"},{"issue":"2","key":"5098_CR105","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.intimp.2015.03.053","volume":"28","author":"T MaruYama","year":"2015","unstructured":"MaruYama T (2015) The nuclear I\u03baB family of proteins controls gene regulation and immune homeostasis. Int Immunopharmacol 28(2):836\u2013840","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"5098_CR106","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.lungcan.2015.06.006","volume":"89","author":"F-ID Dimitrakopoulos","year":"2015","unstructured":"Dimitrakopoulos F-ID et al (2015) Variant of BCL3 gene is strongly associated with five-year survival of non-small-cell lung cancer patients. Lung Cancer 89(3):311\u2013319","journal-title":"Lung Cancer"},{"issue":"7","key":"5098_CR107","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1136\/gutjnl-2014-308270","volume":"65","author":"BC Urban","year":"2016","unstructured":"Urban BC et al (2016) BCL-3 expression promotes colorectal tumorigenesis through activation of AKT signalling. Gut 65(7):1151\u20131164","journal-title":"Gut"},{"issue":"9","key":"5098_CR108","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1158\/1078-0432.CCR-23-0048","volume":"29","author":"DH Al-Rawi","year":"2023","unstructured":"Al-Rawi DH, Rusk N, Friedman CF (2023) The search for genomic biomarkers of response to immunotherapy in ovarian cancer. Clin Cancer Res 29(9):1645\u20131647","journal-title":"Clin Cancer Res"},{"issue":"1","key":"5098_CR109","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1158\/0008-5472.CAN-17-1636","volume":"78","author":"T Maeda","year":"2018","unstructured":"Maeda T et al (2018) MUC1-C induces PD-L1 and immune evasion in triple-negative breast cancer. Can Res 78(1):205\u2013215","journal-title":"Can Res"},{"issue":"8","key":"5098_CR110","doi-asserted-by":"publisher","first-page":"737","DOI":"10.2174\/1568009617666170623113520","volume":"18","author":"L Farahmand","year":"2018","unstructured":"Farahmand L et al (2018) Significant role of MUC1 in development of resistance to currently existing anti-cancer therapeutic agents. Curr Cancer Drug Targets 18(8):737\u2013748","journal-title":"Curr Cancer Drug Targets"},{"issue":"17","key":"5098_CR111","doi-asserted-by":"publisher","first-page":"7013","DOI":"10.1158\/0008-5472.CAN-09-0523","volume":"69","author":"R Ahmad","year":"2009","unstructured":"Ahmad R et al (2009) MUC1-C oncoprotein functions as a direct activator of the nuclear factor-\u03baB p65 transcription factor. Can Res 69(17):7013\u20137021","journal-title":"Can Res"},{"issue":"12","key":"5098_CR112","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/ncb1661","volume":"9","author":"R Ahmad","year":"2007","unstructured":"Ahmad R et al (2007) MUC1 oncoprotein activates the I\u03baB kinase \u03b2 complex and constitutive NF-\u03baB signalling. Nat Cell Biol 9(12):1419\u20131427","journal-title":"Nat Cell Biol"},{"issue":"40","key":"5098_CR113","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1038\/onc.2014.442","volume":"34","author":"H Takahashi","year":"2015","unstructured":"Takahashi H et al (2015) MUC1-C activates the TAK1 inflammatory pathway in colon cancer. Oncogene 34(40):5187\u20135197","journal-title":"Oncogene"},{"issue":"1","key":"5098_CR114","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.molcel.2018.10.034","volume":"73","author":"X Jin","year":"2019","unstructured":"Jin X et al (2019) Phosphorylated RB promotes cancer immunity by inhibiting NF-\u03baB activation and PD-L1 expression. Mol cell 73(1):22\u201335","journal-title":"Mol cell"},{"issue":"1","key":"5098_CR115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-016-0001-8","volume":"6","author":"C-T Wu","year":"2016","unstructured":"Wu C-T et al (2016) The role of PD-L1 in the radiation response and clinical outcome for bladder cancer. Sci Rep 6(1):1\u20139","journal-title":"Sci Rep"},{"issue":"1","key":"5098_CR116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-017-01883-9","volume":"8","author":"H Sato","year":"2017","unstructured":"Sato H et al (2017) DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat Commun 8(1):1\u201311","journal-title":"Nat Commun"},{"issue":"23","key":"5098_CR117","doi-asserted-by":"publisher","first-page":"4452","DOI":"10.1038\/s41388-019-0733-6","volume":"38","author":"TBM Permata","year":"2019","unstructured":"Permata TBM et al (2019) Base excision repair regulates PD-L1 expression in cancer cells. Oncogene 38(23):4452\u20134466","journal-title":"Oncogene"},{"issue":"7","key":"5098_CR118","first-page":"1307","volume":"8","author":"L-L Sun","year":"2018","unstructured":"Sun L-L et al (2018) Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing. Am J Cancer Res 8(7):1307","journal-title":"Am J Cancer Res"},{"issue":"10","key":"5098_CR119","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1093\/annonc\/mdu242","volume":"25","author":"K Azuma","year":"2014","unstructured":"Azuma K et al (2014) Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann Oncol 25(10):1935\u20131940","journal-title":"Ann Oncol"},{"issue":"16","key":"5098_CR120","doi-asserted-by":"publisher","first-page":"14209","DOI":"10.18632\/oncotarget.3694","volume":"6","author":"Y Tang","year":"2015","unstructured":"Tang Y et al (2015) The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs. Oncotarget 6(16):14209","journal-title":"Oncotarget"},{"issue":"5","key":"5098_CR121","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1111\/cas.13989","volume":"110","author":"R Guo","year":"2019","unstructured":"Guo R et al (2019) Hypoxia-inducible factor-1\u03b1 and nuclear factor-\u03baB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells. Cancer Sci 110(5):1665\u20131675","journal-title":"Cancer Sci"},{"issue":"12","key":"5098_CR122","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1158\/1538-7445.AM2022-3724","volume":"82","author":"A Metz","year":"2022","unstructured":"Metz A et al (2022) Abstract 3724: PBRM1 loss in RCC: implications for immunotherapy. Cancer Res 82(12):3724\u20133724","journal-title":"Cancer Res"},{"issue":"30","key":"5098_CR123","doi-asserted-by":"publisher","first-page":"30251","DOI":"10.18632\/oncotarget.4943","volume":"6","author":"G Yao","year":"2015","unstructured":"Yao G et al (2015) LDL suppresses angiogenesis through disruption of the HIF pathway via NF-\u03baB inhibition which is reversed by the proteasome inhibitor BSc2118. Oncotarget 6(30):30251","journal-title":"Oncotarget"},{"issue":"37","key":"5098_CR124","doi-asserted-by":"publisher","first-page":"40247","DOI":"10.18632\/oncotarget.5377","volume":"6","author":"P Mak","year":"2015","unstructured":"Mak P et al (2015) ER\u03b2 regulation of NF-\u03baB activation in prostate cancer is mediated by HIF-1. Oncotarget 6(37):40247","journal-title":"Oncotarget"},{"issue":"1\u20132","key":"5098_CR125","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.bbrc.2015.05.030","volume":"463","author":"K Lin","year":"2015","unstructured":"Lin K et al (2015) EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-\u03baB. Biochem Biophys Res Commun 463(1\u20132):95\u2013101","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"5098_CR126","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.ccell.2016.10.010","volume":"30","author":"S-O Lim","year":"2016","unstructured":"Lim S-O et al (2016) Deubiquitination and stabilization of PD-L1 by CSN5. Cancer Cell 30(6):925\u2013939","journal-title":"Cancer Cell"},{"issue":"8","key":"5098_CR127","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/onc.2016.271","volume":"36","author":"Y Pan","year":"2017","unstructured":"Pan Y et al (2017) Stat3 contributes to cancer progression by regulating Jab1\/Csn5 expression. Oncogene 36(8):1069\u20131079","journal-title":"Oncogene"},{"issue":"6","key":"5098_CR128","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1038\/s41418-019-0460-0","volume":"27","author":"C Liu","year":"2020","unstructured":"Liu C et al (2020) Macrophage-derived CCL5 facilitates immune escape of colorectal cancer cells via the p65\/STAT3-CSN5-PD-L1 pathway. Cell Death Differ 27(6):1765\u20131781","journal-title":"Cell Death Differ"},{"issue":"10","key":"5098_CR129","doi-asserted-by":"publisher","first-page":"5813","DOI":"10.4049\/jimmunol.162.10.5813","volume":"162","author":"MC Brunner","year":"1999","unstructured":"Brunner MC et al (1999) CTLA-4-mediated inhibition of early events of T cell proliferation. J Immunol 162(10):5813\u20135820","journal-title":"J Immunol"},{"issue":"3","key":"5098_CR130","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.4049\/jimmunol.165.3.1352","volume":"165","author":"BM Carreno","year":"2000","unstructured":"Carreno BM et al (2000) CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression. J Immunol 165(3):1352\u20131356","journal-title":"J Immunol"},{"issue":"12","key":"5098_CR131","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1158\/0008-5472.CAN-12-4100","volume":"73","author":"J Duraiswamy","year":"2013","unstructured":"Duraiswamy J et al (2013) Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 73(12):3591\u20133603","journal-title":"Cancer Res"},{"key":"5098_CR132","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/439235","volume":"2012","author":"K Youlin","year":"2012","unstructured":"Youlin K et al (2012) Combination immunotherapy with 4\u20131BBL and CTLA-4 blockade for the treatment of prostate cancer. Clin Dev Immunol 2012:439235","journal-title":"Clin Dev Immunol"},{"issue":"8","key":"5098_CR133","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1158\/1535-7163.MCT-11-1014","volume":"11","author":"L Wu","year":"2012","unstructured":"Wu L et al (2012) CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma. Mol Cancer Ther 11(8):1809\u20131819","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"5098_CR134","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","volume":"59","author":"B Sangro","year":"2013","unstructured":"Sangro B et al (2013) A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 59(1):81\u201388","journal-title":"J Hepatol"},{"issue":"7","key":"5098_CR135","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/CJI.0b013e31829fb7c8","volume":"36","author":"DL Bajor","year":"2013","unstructured":"Bajor DL, Vonderheide RH (2013) Cracking the stone: combination vaccination and ctla-4 blockade in pancreatic cancer. J Immunother 36(7):362\u2013364","journal-title":"J Immunother"},{"issue":"15","key":"5098_CR136","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.1016\/j.cell.2021.05.027","volume":"184","author":"F Marangoni","year":"2021","unstructured":"Marangoni F et al (2021) Expansion of tumor-associated Treg cells upon disruption of a CTLA-4-dependent feedback loop. Cell 184(15):3998\u20134015","journal-title":"Cell"},{"issue":"7129","key":"5098_CR137","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/nature05543","volume":"445","author":"MA Gavin","year":"2007","unstructured":"Gavin MA et al (2007) Foxp3-dependent programme of regulatory T-cell differentiation. Nature 445(7129):771\u2013775","journal-title":"Nature"},{"issue":"8","key":"5098_CR138","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0237465","volume":"15","author":"K Koike","year":"2020","unstructured":"Koike K et al (2020) Prognostic value of FoxP3 and CTLA-4 expression in patients with oral squamous cell carcinoma. PLoS ONE 15(8):e0237465","journal-title":"PLoS ONE"},{"issue":"1","key":"5098_CR139","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/imr.12174","volume":"259","author":"H Morikawa","year":"2014","unstructured":"Morikawa H, Sakaguchi S (2014) Genetic and epigenetic basis of Treg cell development and function: from a FoxP3-centered view to an epigenome-defined view of natural Treg cells. Immunol Rev 259(1):192\u2013205","journal-title":"Immunol Rev"},{"issue":"13","key":"5098_CR140","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1084\/jem.20091411","volume":"206","author":"I Isomura","year":"2009","unstructured":"Isomura I et al (2009) c-Rel is required for the development of thymic Foxp3+ CD4 regulatory T cells. J Exp Med 206(13):3001\u20133014","journal-title":"J Exp Med"},{"issue":"6","key":"5098_CR141","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.immuni.2009.09.022","volume":"31","author":"M Long","year":"2009","unstructured":"Long M et al (2009) Nuclear factor-\u03baB modulates regulatory T cell development by directly regulating expression of Foxp3 transcription factor. Immunity 31(6):921\u2013931","journal-title":"Immunity"},{"issue":"6","key":"5098_CR142","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.immuni.2009.10.006","volume":"31","author":"Q Ruan","year":"2009","unstructured":"Ruan Q et al (2009) Development of Foxp3+ regulatory T cells is driven by the c-Rel enhanceosome. Immunity 31(6):932\u2013940","journal-title":"Immunity"},{"issue":"1","key":"5098_CR143","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1600-065X.2012.01099.x","volume":"246","author":"JA DiDonato","year":"2012","unstructured":"DiDonato JA, Mercurio F, Karin M (2012) NF-\u03baB and the link between inflammation and cancer. Immunol Rev 246(1):379\u2013400","journal-title":"Immunol Rev"},{"issue":"1","key":"5098_CR144","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12943-023-01746-6","volume":"22","author":"X Zhou","year":"2023","unstructured":"Zhou X et al (2023) Targeting RNA N6-methyladenosine to synergize with immune checkpoint therapy. Mol Cancer 22(1):36","journal-title":"Mol Cancer"},{"issue":"3","key":"5098_CR145","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.immuni.2017.08.010","volume":"47","author":"H Oh","year":"2017","unstructured":"Oh H et al (2017) An NF-\u03baB transcription-factor-dependent lineage-specific transcriptional program promotes regulatory T cell identity and function. Immunity 47(3):450\u2013465","journal-title":"Immunity"},{"issue":"21","key":"5098_CR146","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","volume":"25","author":"RV Parry","year":"2005","unstructured":"Parry RV et al (2005) CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 25(21):9543\u20139553","journal-title":"Mol Cell Biol"},{"issue":"7","key":"5098_CR147","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1002\/eji.200323600","volume":"33","author":"S Kubsch","year":"2003","unstructured":"Kubsch S et al (2003) Suppressor activity of anergic T cells induced by IL-10-treated human dendritic cells: association with IL-2-and CTLA-4-dependent G1 arrest of the cell cycle regulated by p27Kip1. Eur J Immunol 33(7):1988\u20131997","journal-title":"Eur J Immunol"},{"key":"5098_CR148","doi-asserted-by":"crossref","unstructured":"Coillie SV, Wiernicki B, Xu J (2020) Molecular and cellular functions of CTLA-4. Regulation of cancer immune checkpoints, pp 7\u201332","DOI":"10.1007\/978-981-15-3266-5_2"},{"issue":"2","key":"5098_CR149","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.immuni.2020.01.018","volume":"52","author":"S Zenke","year":"2020","unstructured":"Zenke S et al (2020) Quorum regulation via nested antagonistic feedback circuits mediated by the receptors CD28 and CTLA-4 confers robustness to T cell population dynamics. Immunity 52(2):313\u2013327","journal-title":"Immunity"},{"key":"5098_CR150","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.3389\/fimmu.2020.608024","volume":"11","author":"D Oyewole-Said","year":"2020","unstructured":"Oyewole-Said D et al (2020) Beyond T-cells: functional characterization of CTLA-4 expression in immune and non-immune cell types. Front Immunol 11:3168","journal-title":"Front Immunol"},{"issue":"6","key":"5098_CR151","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.immuni.2019.11.003","volume":"51","author":"Y Zhao","year":"2019","unstructured":"Zhao Y et al (2019) PD-L1: CD80 cis-heterodimer triggers the co-stimulatory receptor CD28 while repressing the inhibitory PD-1 and CTLA-4 pathways. Immunity 51(6):1059\u20131073","journal-title":"Immunity"},{"issue":"12","key":"5098_CR152","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1200\/JCO.2013.51.3572","volume":"34","author":"MJ Smyth","year":"2014","unstructured":"Smyth MJ, Yagita H, McArthur GA (2014) Combination Anti-CTLA-4 and Anti-RANKL in metastatic melanoma. J Clin Oncol Off J Am Soc Clin Oncol 34(12):e104\u2013e106","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"5098_CR153","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1084\/jem.171.5.1393","volume":"171","author":"F Triebel","year":"1990","unstructured":"Triebel F et al (1990) LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med 171(5):1393\u20131405","journal-title":"J Exp Med"},{"issue":"11","key":"5098_CR154","doi-asserted-by":"publisher","first-page":"5744","DOI":"10.1073\/pnas.94.11.5744","volume":"94","author":"B Huard","year":"1997","unstructured":"Huard B et al (1997) Characterization of the major histocompatibility complex class II binding site on LAG-3 protein. Proc Natl Acad Sci 94(11):5744\u20135749","journal-title":"Proc Natl Acad Sci"},{"issue":"12","key":"5098_CR155","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41590-018-0217-9","volume":"19","author":"T Maruhashi","year":"2018","unstructured":"Maruhashi T et al (2018) LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII. Nat Immunol 19(12):1415\u20131426","journal-title":"Nat Immunol"},{"key":"5098_CR156","doi-asserted-by":"publisher","first-page":"9520","DOI":"10.1200\/JCO.2017.35.15_suppl.9520","volume":"35","author":"PA Ascierto","year":"2017","unstructured":"Ascierto PA et al (2017) Initial efficacy of anti-lymphocyte activation gene-3 (anti\u2013LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti\u2013PD-1\/PD-L1 therapy. Am Soc Clin Oncol 35:9520","journal-title":"Am Soc Clin Oncol"},{"key":"5098_CR157","unstructured":"Camisaschi C et al (2014) Alternative activation of human plasmacytoid DCs"},{"key":"5098_CR158","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.3389\/fimmu.2018.02783","volume":"9","author":"AC Belkina","year":"2018","unstructured":"Belkina AC et al (2018) Multivariate computational analysis of gamma delta T cell inhibitory receptor signatures reveals the divergence of healthy and ART-suppressed HIV+ aging. Front Immunol 9:2783","journal-title":"Front Immunol"},{"key":"5098_CR159","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.88628","author":"D Golden","year":"2016","unstructured":"Golden D et al (2016) Lymphocyte activation gene 3 and coronary artery disease. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.88628","journal-title":"JCI Insight"},{"issue":"1","key":"5098_CR160","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/mi.2015.45","volume":"9","author":"J Do","year":"2016","unstructured":"Do J et al (2016) An IL-27\/Lag3 axis enhances Foxp3+ regulatory T cell\u2013suppressive function and therapeutic efficacy. Mucosal Immunol 9(1):137\u2013145","journal-title":"Mucosal Immunol"},{"issue":"7764","key":"5098_CR161","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","volume":"571","author":"O Khan","year":"2019","unstructured":"Khan O et al (2019) TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Nature 571(7764):211\u2013218","journal-title":"Nature"},{"key":"5098_CR162","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.immuni.2015.01.006","volume":"42","author":"G Martinez","year":"2015","unstructured":"Martinez G, Pereira R, \u00c4ij\u00f6 T, Kim EY, Marangoni F, Pipkin ME, Togher S, Heissmeyer V, Zhang YC, Crotty S, Lamperti ED, Ansel KM, Mempel TR, L\u00e4hdesm\u00e4ki H, Hogan PG, Rao A (2015) The transcription factor NFAT promotes exhaustion of activated CD8 + T cells. Immunity 42:265\u2013278","journal-title":"Immunity"},{"issue":"10","key":"5098_CR163","doi-asserted-by":"publisher","first-page":"5392","DOI":"10.4049\/jimmunol.169.10.5392","volume":"169","author":"CJ Workman","year":"2002","unstructured":"Workman CJ, Dugger KJ, Vignali DA (2002) Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3. J Immunol 169(10):5392\u20135395","journal-title":"J Immunol"},{"issue":"4","key":"5098_CR164","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/eji.200323382","volume":"33","author":"CJ Workman","year":"2003","unstructured":"Workman CJ, Vignali DA (2003) The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells. Eur J Immunol 33(4):970\u2013979","journal-title":"Eur J Immunol"},{"issue":"2","key":"5098_CR165","doi-asserted-by":"publisher","first-page":"688","DOI":"10.4049\/jimmunol.174.2.688","volume":"174","author":"CJ Workman","year":"2005","unstructured":"Workman CJ, Vignali DA (2005) Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223). J Immunol 174(2):688\u2013695","journal-title":"J Immunol"},{"issue":"13","key":"5098_CR166","doi-asserted-by":"publisher","first-page":"12430","DOI":"10.1074\/jbc.M410420200","volume":"280","author":"M Koyanagi","year":"2005","unstructured":"Koyanagi M et al (2005) Centrosomal P4. 1-associated protein is a new member of transcriptional coactivators for nuclear factor-\u03baB. J Biol Chem 280(13):12430\u201312437","journal-title":"J Biol Chem"},{"issue":"9","key":"5098_CR167","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1210\/me.2002-0108","volume":"16","author":"B Peng","year":"2002","unstructured":"Peng B et al (2002) CPAP is a novel stat5-interacting cofactor that augments stat5-mediated transcriptional activity. Mol Endocrinol 16(9):2019\u20132033","journal-title":"Mol Endocrinol"},{"key":"5098_CR168","doi-asserted-by":"publisher","first-page":"3444","DOI":"10.3389\/fimmu.2020.615317","volume":"11","author":"CG Graydon","year":"2021","unstructured":"Graydon CG, Mohideen S, Fowke KR (2021) LAG3\u2019s enigmatic mechanism of action. Front Immunol 11:3444","journal-title":"Front Immunol"},{"issue":"5","key":"5098_CR169","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.4049\/jimmunol.1103474","volume":"189","author":"MQ Ge","year":"2012","unstructured":"Ge MQ et al (2012) NK cells regulate CD8+ T cell priming and dendritic cell migration during influenza A infection by IFN-\u03b3 and perforin-dependent mechanisms. J Immunol 189(5):2099\u20132109","journal-title":"J Immunol"},{"issue":"1","key":"5098_CR170","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.celrep.2019.03.004","volume":"27","author":"DM Previte","year":"2019","unstructured":"Previte DM et al (2019) Lymphocyte activation gene-3 maintains mitochondrial and metabolic quiescence in naive CD4+ T cells. Cell Rep 27(1):129\u2013141","journal-title":"Cell Rep"},{"issue":"7","key":"5098_CR171","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1023\/B:GLYC.0000014072.34840.04","volume":"19","author":"H Leffler","year":"2002","unstructured":"Leffler H et al (2002) Introduction to galectins. Glycoconj J 19(7):433\u2013440","journal-title":"Glycoconj J"},{"issue":"4","key":"5098_CR172","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1158\/2326-6066.CIR-14-0150","volume":"3","author":"T Kouo","year":"2015","unstructured":"Kouo T et al (2015) Galectin-3 shapes antitumor immune responses by suppressing CD8+ T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells. Cancer Immunol Res 3(4):412\u2013423","journal-title":"Cancer Immunol Res"},{"issue":"34","key":"5098_CR173","doi-asserted-by":"publisher","first-page":"29913","DOI":"10.1074\/jbc.M111.226423","volume":"286","author":"AI Markowska","year":"2011","unstructured":"Markowska AI, Jefferies KC, Panjwani N (2011) Galectin-3 protein modulates cell surface expression and activation of vascular endothelial growth factor receptor 2 in human endothelial cells. J Biol Chem 286(34):29913\u201329921","journal-title":"J Biol Chem"},{"issue":"5","key":"5098_CR174","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/ncb2953","volume":"16","author":"L Seguin","year":"2014","unstructured":"Seguin L et al (2014) An integrin \u03b23\u2013KRAS\u2013RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat Cell Biol 16(5):457\u2013468","journal-title":"Nat Cell Biol"},{"issue":"8","key":"5098_CR175","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s10585-011-9406-8","volume":"28","author":"S-J Kim","year":"2011","unstructured":"Kim S-J et al (2011) Galectin-3 germline variant at position 191 enhances nuclear accumulation and activation of \u03b2-catenin in gastric cancer. Clin Exp Metas 28(8):743\u2013750","journal-title":"Clin Exp Metas"},{"key":"5098_CR176","doi-asserted-by":"crossref","unstructured":"Kim, S.J., et al., Galectin-3 increases gastric cancer cell motility by up-regulating fascin-1 expression. Gastroenterology, 2010. 138(3): p. 1035\u20131045. e2.","DOI":"10.1053\/j.gastro.2009.09.061"},{"issue":"6871","key":"5098_CR177","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/415536a","volume":"415","author":"L Monney","year":"2002","unstructured":"Monney L et al (2002) Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 415(6871):536\u2013541","journal-title":"Nature"},{"issue":"12","key":"5098_CR178","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1038\/ni739","volume":"2","author":"JJ McIntire","year":"2001","unstructured":"McIntire JJ et al (2001) Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family. Nat Immunol 2(12):1109\u20131116","journal-title":"Nat Immunol"},{"issue":"8","key":"5098_CR179","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/gene.2011.75","volume":"12","author":"J Lee","year":"2011","unstructured":"Lee J et al (2011) TIM polymorphisms\u2014genetics and function. Genes Immun 12(8):595\u2013604","journal-title":"Genes Immun"},{"issue":"7710","key":"5098_CR180","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41586-018-0206-z","volume":"558","author":"N Chihara","year":"2018","unstructured":"Chihara N et al (2018) Induction and transcriptional regulation of the co-inhibitory gene module in T cells. Nature 558(7710):454\u2013459","journal-title":"Nature"},{"issue":"1","key":"5098_CR181","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4049\/immunohorizons.1800083","volume":"3","author":"JH DeLong","year":"2019","unstructured":"DeLong JH et al (2019) IL-27 and TCR stimulation promote T cell expression of multiple inhibitory receptors. Immunohorizons 3(1):13\u201325","journal-title":"Immunohorizons"},{"issue":"10","key":"5098_CR182","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1084\/jem.20100637","volume":"207","author":"J Fourcade","year":"2010","unstructured":"Fourcade J et al (2010) Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen\u2013specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 207(10):2175\u20132186","journal-title":"J Exp Med"},{"issue":"10","key":"5098_CR183","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1084\/jem.20100643","volume":"207","author":"K Sakuishi","year":"2010","unstructured":"Sakuishi K et al (2010) Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 207(10):2187\u20132194","journal-title":"J Exp Med"},{"issue":"10","key":"5098_CR184","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-11-0096","volume":"71","author":"SF Ngiow","year":"2011","unstructured":"Ngiow SF et al (2011) Anti-TIM3 antibody promotes T cell IFN-\u03b3\u2013mediated antitumor immunity and suppresses established tumors. Can Res 71(10):3540\u20133551","journal-title":"Can Res"},{"issue":"17","key":"5098_CR185","first-page":"4501","volume":"117","author":"Q Zhou","year":"2011","unstructured":"Zhou Q et al (2011) Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood J Am Soc Hematol 117(17):4501\u20134510","journal-title":"Blood J Am Soc Hematol"},{"issue":"5","key":"5098_CR186","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-018-0528-7","volume":"9","author":"J Ji","year":"2018","unstructured":"Ji J et al (2018) Long non-coding RNA Lnc-Tim3 exacerbates CD8 T cell exhaustion via binding to Tim-3 and inducing nuclear translocation of Bat3 in HCC. Cell Death Dis 9(5):1\u201311","journal-title":"Cell Death Dis"},{"issue":"9","key":"5098_CR187","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/nm.2871","volume":"18","author":"M Rangachari","year":"2012","unstructured":"Rangachari M et al (2012) Bat3 promotes T cell responses and autoimmunity by repressing Tim-3\u2013mediated cell death and exhaustion. Nat Med 18(9):1394\u20131400","journal-title":"Nat Med"},{"issue":"7","key":"5098_CR188","doi-asserted-by":"publisher","first-page":"3417","DOI":"10.4049\/jimmunol.1400395","volume":"193","author":"N Maurya","year":"2014","unstructured":"Maurya N et al (2014) Immunoregulation of dendritic cells by the receptor T cell Ig and mucin protein-3 via Bruton\u2019s tyrosine kinase and c-Src. J Immunol 193(7):3417\u20133425","journal-title":"J Immunol"},{"issue":"1","key":"5098_CR189","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ccell.2017.11.019","volume":"33","author":"\u00c1 de Mingo Pulido","year":"2018","unstructured":"de Mingo Pulido \u00c1 et al (2018) TIM-3 regulates CD103+ dendritic cell function and response to chemotherapy in breast cancer. Cancer Cell 33(1):60\u201374","journal-title":"Cancer Cell"},{"issue":"9","key":"5098_CR190","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/ni.2376","volume":"13","author":"S Chiba","year":"2012","unstructured":"Chiba S et al (2012) Tumor-infiltrating DCs suppress nucleic acid\u2013mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol 13(9):832\u2013842","journal-title":"Nat Immunol"},{"issue":"1","key":"5098_CR191","first-page":"52","volume":"17","author":"M Lin","year":"2020","unstructured":"Lin M et al (2020) The immunomodulatory effects and mechanisms of Tim-3 action in the early stage of mice with severe acute pancreatitis. Iran J Immunol 17(1):52\u201363","journal-title":"Iran J Immunol"},{"issue":"6","key":"5098_CR192","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s00392-018-1398-9","volume":"108","author":"D Zheng","year":"2019","unstructured":"Zheng D et al (2019) MicroRNA-214 promotes the calcification of human aortic valve interstitial cells through the acceleration of inflammatory reactions with activated MyD88\/NF-\u03baB signaling. Clin Res Cardiol 108(6):691\u2013702","journal-title":"Clin Res Cardiol"},{"issue":"1","key":"5098_CR193","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3892\/ijmm.2015.2410","volume":"37","author":"G Li","year":"2016","unstructured":"Li G et al (2016) TLR4-mediated NF-\u03baB signaling pathway mediates HMGB1-induced pancreatic injury in mice with severe acute pancreatitis. Int J Mol Med 37(1):99\u2013107","journal-title":"Int J Mol Med"},{"issue":"10","key":"5098_CR194","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.imbio.2012.01.012","volume":"217","author":"MJ Lee","year":"2012","unstructured":"Lee MJ et al (2012) Down-regulation of interleukin-2 production by CD4(+) T cells expressing TIM-3 through suppression of NFAT dephosphorylation and AP-1 transcription. Immunobiology 217(10):986\u2013995","journal-title":"Immunobiology"},{"key":"5098_CR195","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1002\/jcb.27562","volume":"120","author":"X Liu","year":"2018","unstructured":"Liu X et al (2018) Dysregulation of FTX\/miR-545 signaling pathway downregulates Tim-3 and is responsible for the abnormal activation of macrophage in cirrhosis. J Cell Biochem 120:2336","journal-title":"J Cell Biochem"},{"issue":"4","key":"5098_CR196","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12851","volume":"91","author":"L Zhao","year":"2020","unstructured":"Zhao L et al (2020) Cross-regulation by TLR4 and T cell Ig mucin-3 determines severity of liver injury in a CCl4-induced mouse model. Scand J Immunol 91(4):e12851","journal-title":"Scand J Immunol"},{"issue":"11","key":"5098_CR197","doi-asserted-by":"publisher","first-page":"6411","DOI":"10.4049\/jimmunol.176.11.6411","volume":"176","author":"S Frisancho-Kiss","year":"2006","unstructured":"Frisancho-Kiss S et al (2006) Cutting edge: T cell Ig mucin-3 reduces inflammatory heart disease by increasing CTLA-4 during innate immunity. J Immunol 176(11):6411\u20136415","journal-title":"J Immunol"},{"issue":"3","key":"5098_CR198","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.stem.2015.07.011","volume":"17","author":"Y Kikushige","year":"2015","unstructured":"Kikushige Y et al (2015) A TIM-3\/Gal-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemic progression. Cell Stem Cell 17(3):341\u2013352","journal-title":"Cell Stem Cell"},{"issue":"1","key":"5098_CR199","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/ni.1674","volume":"10","author":"X Yu","year":"2009","unstructured":"Yu X et al (2009) The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol 10(1):48\u201357","journal-title":"Nat Immunol"},{"issue":"3","key":"5098_CR200","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/eji.200839116","volume":"39","author":"KS Boles","year":"2009","unstructured":"Boles KS et al (2009) A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC. Eur J Immunol 39(3):695\u2013703","journal-title":"Eur J Immunol"},{"issue":"42","key":"5098_CR201","doi-asserted-by":"publisher","first-page":"17858","DOI":"10.1073\/pnas.0903474106","volume":"106","author":"N Stanietsky","year":"2009","unstructured":"Stanietsky N et al (2009) The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci U S A 106(42):17858\u201317863","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"5098_CR202","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.it.2016.10.002","volume":"38","author":"NA Manieri","year":"2017","unstructured":"Manieri NA, Chiang EY, Grogan JL (2017) TIGIT: a key inhibitor of the cancer immunity cycle. Trends Immunol 38(1):20\u201328","journal-title":"Trends Immunol"},{"issue":"1","key":"5098_CR203","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/JID.2015.404","volume":"136","author":"T Inozume","year":"2016","unstructured":"Inozume T et al (2016) Melanoma cells control antimelanoma CTL responses via interaction between TIGIT and CD155 in the effector phase. J Invest Dermatol 136(1):255\u2013263","journal-title":"J Invest Dermatol"},{"issue":"2","key":"5098_CR204","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000957","volume":"8","author":"J-M Chauvin","year":"2020","unstructured":"Chauvin J-M, Zarour HM (2020) TIGIT in cancer immunotherapy. J Immunother Cancer 8(2):e000957","journal-title":"J Immunother Cancer"},{"issue":"1","key":"5098_CR205","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s42003-020-0845-0","volume":"3","author":"N Patsoukis","year":"2020","unstructured":"Patsoukis N et al (2020) Interaction of SHP-2 SH2 domains with PD-1 ITSM induces PD-1 dimerization and SHP-2 activation. Commun Biol 3(1):1\u201313","journal-title":"Commun Biol"},{"issue":"26","key":"5098_CR206","doi-asserted-by":"publisher","first-page":"18177","DOI":"10.1074\/jbc.M709715200","volume":"283","author":"CH Reynolds","year":"2008","unstructured":"Reynolds CH et al (2008) Phosphorylation regulates tau interactions with Src homology 3 domains of phosphatidylinositol 3-kinase, phospholipase C\u03b31, Grb2, and Src family kinases. J Biol Chem 283(26):18177\u201318186","journal-title":"J Biol Chem"},{"issue":"1","key":"5098_CR207","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms6456","volume":"5","author":"N Engels","year":"2014","unstructured":"Engels N et al (2014) The immunoglobulin tail tyrosine motif upgrades memory-type BCRs by incorporating a Grb2-Btk signalling module. Nat Commun 5(1):1\u201311","journal-title":"Nat Commun"},{"issue":"25","key":"5098_CR208","doi-asserted-by":"publisher","first-page":"17647","DOI":"10.1074\/jbc.M114.572420","volume":"289","author":"M Li","year":"2014","unstructured":"Li M et al (2014) T-cell immunoglobulin and ITIM domain (TIGIT) receptor\/poliovirus receptor (PVR) ligand engagement suppresses interferon-\u03b3 production of natural killer cells via \u03b2-arrestin 2-mediated negative signaling. J Biol Chem 289(25):17647\u201317657","journal-title":"J Biol Chem"},{"issue":"3","key":"5098_CR209","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/cdd.2012.141","volume":"20","author":"S Liu","year":"2013","unstructured":"Liu S et al (2013) Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells. Cell Death Differ 20(3):456\u2013464","journal-title":"Cell Death Differ"},{"key":"5098_CR210","doi-asserted-by":"publisher","first-page":"100252","DOI":"10.1016\/j.mtadv.2022.100252","volume":"15","author":"BV Lima","year":"2022","unstructured":"Lima BV et al (2022) Harnessing chitosan and poly-(\u03b3-glutamic acid)-based biomaterials towards cancer immunotherapy. Mater Today Adv 15:100252","journal-title":"Mater Today Adv"},{"key":"5098_CR211","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1146\/annurev.immunol.23.021704.115611","volume":"23","author":"RJ Greenwald","year":"2005","unstructured":"Greenwald RJ, Freeman GJ, Sharpe AH (2005) The B7 family revisited. Annu Rev Immunol 23:515\u2013548","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"5098_CR212","doi-asserted-by":"publisher","first-page":"336","DOI":"10.4049\/jimmunol.1701025","volume":"200","author":"MA Kunicki","year":"2018","unstructured":"Kunicki MA et al (2018) Identity and diversity of human peripheral Th and T regulatory cells defined by single-cell mass cytometry. J Immunol 200(1):336\u2013346","journal-title":"J Immunol"},{"issue":"1","key":"5098_CR213","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.immuni.2016.11.005","volume":"46","author":"Y Simoni","year":"2017","unstructured":"Simoni Y et al (2017) Human innate lymphoid cell subsets possess tissue-type based heterogeneity in phenotype and frequency. Immunity 46(1):148\u2013161","journal-title":"Immunity"},{"issue":"1","key":"5098_CR214","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/imr.12739","volume":"288","author":"VR Fonseca","year":"2019","unstructured":"Fonseca VR, Ribeiro F, Graca L (2019) T follicular regulatory (Tfr) cells: dissecting the complexity of Tfr-cell compartments. Immunol Rev 288(1):112\u2013127","journal-title":"Immunol Rev"},{"issue":"3","key":"5098_CR215","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.coi.2010.01.001","volume":"22","author":"TR Simpson","year":"2010","unstructured":"Simpson TR, Quezada SA, Allison JP (2010) Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS). Curr Opin Immunol 22(3):326\u2013332","journal-title":"Curr Opin Immunol"},{"issue":"6","key":"5098_CR216","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.immuni.2008.03.018","volume":"28","author":"T Ito","year":"2008","unstructured":"Ito T et al (2008) Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery. Immunity 28(6):870\u2013880","journal-title":"Immunity"},{"issue":"1","key":"5098_CR217","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1084\/jem.20131142","volume":"211","author":"KS Smigiel","year":"2014","unstructured":"Smigiel KS et al (2014) CCR7 provides localized access to IL-2 and defines homeostatically distinct regulatory T cell subsets. J Exp Med 211(1):121\u2013136","journal-title":"J Exp Med"},{"issue":"4","key":"5098_CR218","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/ni.2006","volume":"12","author":"E Cretney","year":"2011","unstructured":"Cretney E et al (2011) The transcription factors Blimp-1 and IRF4 jointly control the differentiation and function of effector regulatory T cells. Nat Immunol 12(4):304\u2013311","journal-title":"Nat Immunol"},{"issue":"7236","key":"5098_CR219","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/nature07674","volume":"458","author":"Y Zheng","year":"2009","unstructured":"Zheng Y et al (2009) Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T(H)2 responses. Nature 458(7236):351\u2013356","journal-title":"Nature"},{"issue":"1","key":"5098_CR220","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/imm.13178","volume":"160","author":"M Ono","year":"2020","unstructured":"Ono M (2020) Control of regulatory T-cell differentiation and function by T-cell receptor signalling and Foxp3 transcription factor complexes. Immunology 160(1):24\u201337","journal-title":"Immunology"},{"key":"5098_CR221","doi-asserted-by":"publisher","first-page":"S199","DOI":"10.1016\/j.semcancer.2015.02.007","volume":"35","author":"SC Casey","year":"2015","unstructured":"Casey SC et al (2015) Cancer prevention and therapy through the modulation of the tumor microenvironment. Semin Cancer Biol 35:S199\u2013S223","journal-title":"Semin Cancer Biol"},{"issue":"11","key":"5098_CR222","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1111\/febs.13645","volume":"283","author":"E Gonz\u00e1lez-Su\u00e1rez","year":"2016","unstructured":"Gonz\u00e1lez-Su\u00e1rez E, Sanz-Moreno A (2016) RANK as a therapeutic target in cancer. FEBS J 283(11):2018\u20132033","journal-title":"FEBS J"},{"issue":"3","key":"5098_CR223","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2217\/fon-2017-0124","volume":"14","author":"R Santana-Davila","year":"2018","unstructured":"Santana-Davila R, Chow LQ (2018) The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer. Future Oncol 14(3):191\u2013194","journal-title":"Future Oncol"},{"issue":"12","key":"5098_CR224","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1200\/JCO.2013.51.3572","volume":"34","author":"MJ Smyth","year":"2016","unstructured":"Smyth MJ, Yagita H, McArthur GA (2016) Combination Anti-CTLA-4 and Anti-RANKL in metastatic melanoma. J Clin Oncol 34(12):e104\u2013e106","journal-title":"J Clin Oncol"},{"issue":"6","key":"5098_CR225","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1431088","volume":"7","author":"E Ahern","year":"2018","unstructured":"Ahern E et al (2018) RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer. Oncoimmunology 7(6):e1431088","journal-title":"Oncoimmunology"},{"issue":"19","key":"5098_CR226","doi-asserted-by":"publisher","first-page":"5789","DOI":"10.1158\/1078-0432.CCR-17-0606","volume":"23","author":"E Ahern","year":"2017","unstructured":"Ahern E et al (2017) Co-administration of RANKL and CTLA4 antibodies enhances lymphocyte-mediated antitumor immunity in mice. Clin Cancer Res 23(19):5789\u20135801","journal-title":"Clin Cancer Res"},{"issue":"12","key":"5098_CR227","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1016\/j.ejso.2017.09.018","volume":"43","author":"PA van Dam","year":"2017","unstructured":"van Dam PA, Rolfo C, Ruiz R (2017) Neoadjuvant trials can accelerate research on novel systemic treatment modalities in cancer of the uterine cervix. Eur J Surg Oncol 43(12):2245\u20132247","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"5098_CR228","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2018-000352","volume":"3","author":"PA van Dam","year":"2018","unstructured":"van Dam PA et al (2018) Potential new biomarkers for squamous carcinoma of the uterine cervix. ESMO Open 3(4):e000352","journal-title":"ESMO Open"},{"issue":"1","key":"5098_CR229","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1186\/s12885-019-5676-3","volume":"19","author":"S Tuyaerts","year":"2019","unstructured":"Tuyaerts S et al (2019) PRIMMO study protocol: a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer. BMC Cancer 19(1):506","journal-title":"BMC Cancer"},{"issue":"4","key":"5098_CR230","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s10495-009-0315-0","volume":"14","author":"HM Shen","year":"2009","unstructured":"Shen HM, Tergaonkar V (2009) NFkappaB signaling in carcinogenesis and as a potential molecular target for cancer therapy. Apoptosis 14(4):348\u2013363","journal-title":"Apoptosis"},{"issue":"5","key":"5098_CR231","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.cell.2007.07.009","volume":"130","author":"FR Greten","year":"2007","unstructured":"Greten FR et al (2007) NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell 130(5):918\u2013931","journal-title":"Cell"},{"issue":"1","key":"5098_CR232","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-019-0779-5","volume":"12","author":"A Akinleye","year":"2019","unstructured":"Akinleye A, Rasool Z (2019) Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol 12(1):92","journal-title":"J Hematol Oncol"},{"issue":"3","key":"5098_CR233","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2174\/092986707779941113","volume":"14","author":"MA Calzado","year":"2007","unstructured":"Calzado MA, Bacher S, Schmitz ML (2007) NF-kappaB inhibitors for the treatment of inflammatory diseases and cancer. Curr Med Chem 14(3):367\u2013376","journal-title":"Curr Med Chem"},{"key":"5098_CR234","doi-asserted-by":"publisher","first-page":"117793222210917","DOI":"10.1177\/11779322221091740","volume":"16","author":"TL Wargasetia","year":"2022","unstructured":"Wargasetia TL, Ratnawati H, Widodo N (2022) Sea cucumber compounds targeting NF-\u03baB in cancer treatment. Bioinform Biol Insights 16:11779322221091740","journal-title":"Bioinform Biol Insights"},{"issue":"4","key":"5098_CR235","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1080\/14740338.2017.1300656","volume":"16","author":"MJ Ahn","year":"2017","unstructured":"Ahn MJ et al (2017) EGFR TKI combination with immunotherapy in non-small cell lung cancer. Expert Opin Drug Saf 16(4):465\u2013469","journal-title":"Expert Opin Drug Saf"},{"issue":"7","key":"5098_CR236","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1158\/2326-6066.CIR-22-0815","volume":"11","author":"K Kawase","year":"2023","unstructured":"Kawase K et al (2023) High expression of MHC class I overcomes cancer immunotherapy resistance due to IFN\u03b3 signaling pathway defects. Cancer Immunol Res 11(7):895\u2013908","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"5098_CR237","doi-asserted-by":"publisher","first-page":"eaay7785","DOI":"10.1126\/sciadv.aay7785","volume":"6","author":"Z Xiao","year":"2020","unstructured":"Xiao Z et al (2020) Dual pH-sensitive nanodrug blocks PD-1 immune checkpoint and uses T cells to deliver NF-\u03baB inhibitor for antitumor immunotherapy. Sci Adv 6(6):eaay7785","journal-title":"Sci Adv"},{"issue":"7756","key":"5098_CR238","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/s41586-019-1162-y","volume":"569","author":"E Perez-Ruiz","year":"2019","unstructured":"Perez-Ruiz E et al (2019) Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature 569(7756):428\u2013432","journal-title":"Nature"},{"issue":"1","key":"5098_CR239","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s13046-018-0926-9","volume":"37","author":"Y Peng","year":"2018","unstructured":"Peng Y et al (2018) Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway. J Exp Clin Cancer Res 37(1):248","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"5098_CR240","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.pan.2018.02.006","volume":"18","author":"C Zuo","year":"2018","unstructured":"Zuo C et al (2018) Celecoxib suppresses proliferation and metastasis of pancreatic cancer cells by down-regulating STAT3\/NF-kB and L1CAM activities. Pancreatology 18(3):328\u2013333","journal-title":"Pancreatology"},{"issue":"2","key":"5098_CR241","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1074374","volume":"5","author":"Y Li","year":"2016","unstructured":"Li Y et al (2016) Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity. Oncoimmunology 5(2):e1074374","journal-title":"Oncoimmunology"},{"issue":"1","key":"5098_CR242","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molcel.2018.12.012","volume":"73","author":"SJ Kim","year":"2019","unstructured":"Kim SJ, Asfaha S, Dick FA (2019) CDK4 inhibitors thwart immunity by inhibiting phospho-RB-NF-\u03baB complexes. Mol Cell 73(1):1\u20132","journal-title":"Mol Cell"},{"issue":"16","key":"5098_CR243","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood SS et al (2018) Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 71(16):1755\u20131764","journal-title":"J Am Coll Cardiol"},{"key":"5098_CR244","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ijcard.2019.05.028","volume":"292","author":"V Quagliariello","year":"2019","unstructured":"Quagliariello V et al (2019) Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab. Int J Cardiol 292:171\u2013179","journal-title":"Int J Cardiol"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-023-05098-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-023-05098-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-023-05098-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T04:43:58Z","timestamp":1709181838000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-023-05098-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":244,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["5098"],"URL":"https:\/\/doi.org\/10.1007\/s00018-023-05098-8","relation":{},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,29]]},"assertion":[{"value":"2 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 February 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"106"}}